Core Viewpoint - Xianjian Technology (01302) has seen a stock price increase of over 4%, currently trading at 1.65 HKD, with a transaction volume of 43.52 million HKD following the announcement of regulatory approval for its G-iliacPro iliac artery stent system [1] Group 1 - The G-iliacPro system has received official registration approval from the National Medical Products Administration of China, effective January 7, 2026 [1] - This product is designed for endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms [1] - The system aims to enhance pelvic blood supply by reconstructing the internal iliac artery, providing a more mature and comprehensive solution for clinical applications, representing a systematic upgrade over existing treatment options [1]
港股异动 | 先健科技(01302)现涨超4% G-iliacPro髂动脉覆膜支架系统获药监局正式注册批准